search button

Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR‑TKI‑sensitive, primary resistant and acquired resistant human non‑small cell lung cancer cells

  • Authors:
    • Min Wu
    • Yuan Yuan
    • Yue‑Yin Pan
    • Ying Zhang

  • View Affiliations

  • Published online on: March 28, 2014     https://doi.org/10.3892/mmr.2014.2082
  • Pages: 2417-2422
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In a number of large clinical studies, concurrent administration of the epidermal growth factor receptor‑tyrosine kinase inhibitor (EGFR‑TKI) with cytotoxic chemotherapy has failed to improve the survival rate in unselected patients with advanced non‑small cell lung cancer (NSCLC). The purpose of the current study was to investigate the antitumor effects of gefitinib in combination with docetaxel in EGFR‑TKI‑sensitive, primary resistant and acquired resistant human lung cancer cell lines and the associated molecular mechanisms. EGFR‑TKI‑sensitive and EGFR‑TKI‑resistant human lung cancer cell lines were exposed to gefitinib or docetaxel alone, or in combination. Cell viability was assessed using the MTT assay. Cell cycle distribution and apoptosis were measured by flow cytometry and alterations in signaling pathways were examined by immunoblotting. The cytotoxic interaction between docetaxel and gefitinib was determined by combination index (CI) analysis. Coadministration of gefitinib and docetaxel was observed to result in superior inhibition of tumor cell proliferation, however, increased rates of apoptosis were only observed in EGFR‑TKI‑sensitive cells, whereas, antagonistic activity was observed in the EGFR‑TKI‑resistant cell lines. Gefitinib arrested the cell cycle at the G1 phase, whereas docetaxel arrested the cell cycle at the S phase. In addition, in cells exhibiting a synergistic interaction between gefitinib and docetaxel, an increase in p‑EGFR and p‑AKT was observed following chemotherapy exposure. By contrast, in cells exhibiting no change or a decrease in p‑EGFR and p‑AKT following docetaxel treatment, an antagonistic interaction between the two agents was observed. In conclusion, the combination of docetaxel and gefitinib generated synergistic effects in EGFR‑TKI‑sensitive cells and antagonistic effects in EGFR‑TKI‑primary and acquired resistant cells, suggesting that EGFR‑TKIs, combined with docetaxel, may be beneficial to NSCLC patients with EGFR mutations. The results also indicate that the interactions between gefitinib and docetaxel may be associated with the effect of docetaxel on EGFR phosphorylation.
View Figures
View References

Related Articles

Journal Cover

June-2014
Volume 9 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
  • CiteScore: 6.9
  • CiteScore Rank: Q2: #98/328 Biochemistry, Genetics and Molecular Biology
  • Source Normalized Impact per Paper (SNIP): 0.721
  • SCImago Journal Rank (SJR): 0.65
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Wu M, Yuan Y, Pan YY and Zhang Y: Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR‑TKI‑sensitive, primary resistant and acquired resistant human non‑small cell lung cancer cells. Mol Med Rep 9: 2417-2422, 2014
APA
Wu, M., Yuan, Y., Pan, Y., & Zhang, Y. (2014). Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR‑TKI‑sensitive, primary resistant and acquired resistant human non‑small cell lung cancer cells. Molecular Medicine Reports, 9, 2417-2422. https://doi.org/10.3892/mmr.2014.2082
MLA
Wu, M., Yuan, Y., Pan, Y., Zhang, Y."Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR‑TKI‑sensitive, primary resistant and acquired resistant human non‑small cell lung cancer cells". Molecular Medicine Reports 9.6 (2014): 2417-2422.
Chicago
Wu, M., Yuan, Y., Pan, Y., Zhang, Y."Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR‑TKI‑sensitive, primary resistant and acquired resistant human non‑small cell lung cancer cells". Molecular Medicine Reports 9, no. 6 (2014): 2417-2422. https://doi.org/10.3892/mmr.2014.2082